Risk factors and predictive biomarkers of immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer

doi:10.3760/cma.j.cn371439-20210115-00057

Abstract

Abstract:

The use of immune checkpoint inhibitors (ICIs) has changed the clinical outcome of non-small cell lung cancer (NSCLC), with the widespread application of ICIs, immune-related adverse events (irAEs) have also appeared. Immune checkpoint inhibitor pneumonitis (CIP) is a serious adverse event of ICIs treatment that needs attention. Therefore, early identification of high-risk groups of CIPs and early intervention can reduce the occurrence of permanent drug withdrawal and severe CIPs, thereby improving patients' prognosis.

Key words: Carcinoma,non-small-cell lung, Immune checkpoint inhibitors, Risk factors, Biomarkers

Wang Hui, Xia Rong, Wei Qingwen, Wan Yixin. Risk factors and predictive biomarkers of immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer[J]. Journal of International Oncology, 2021, 48(5): 296-301.

References 55

[1]	Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J]. Lancet Oncol, 2017,18(1):31-41. DOI: 10.1016/s1470-2045(16)30624-6. doi: 10.1016/S1470-2045(16)30624-6
[2]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015,373(2):123-135. DOI: 10.1056/NEJMoa1504627. doi: 10.1056/NEJMoa1504627
[3]	Suresh K, Psoter KJ, Voong KR, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy[J]. Thorac Oncol, 2019,14(3):494-502. DOI: 10.1016/j.jtho.2018.11.016. doi: 10.1016/j.jtho.2018.11.016
[4]	Ma K, Lu Y, Jiang S, et al. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis[J]. Front Pharmacol, 2018,9:1430. DOI: 10.3389/fphar.2018.01430. doi: 10.3389/fphar.2018.01430
[5]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017,389(10066):255-265. DOI: 10.1016/s0140-6736(16)32517-x. doi: S0140-6736(16)32517-X pmid: 27979383
[6]	Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors[J]. J Thorac Oncol, 2018,13(12):1930-1939. DOI: 10.1016/j.jtho.2018.08.2035. doi: 10.1016/j.jtho.2018.08.2035
[7]	Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018,125:150-156. DOI: 10.1016/j.lungcan.2018.09.015. doi: 10.1016/j.lungcan.2018.09.015
[8]	Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis[J]. Lung Cancer, 2018,125:212-217. DOI: 10.1016/j.lungcan.2018.10.001. doi: S0169-5002(18)30585-3 pmid: 30429022
[9]	Suzuki Y, Karayama M, Uto T, et al. Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study[J]. J Thorac Oncol, 2020,15(8):1317-1327. DOI: 10.1016/j.jtho.2020.04.002. doi: S1556-0864(20)30297-5 pmid: 32289515
[10]	Naqash AR, Ricciuti B, Owen DH, et al. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort[J]. Cancer Immunol Immunother, 2020,69(7):1177-1187. DOI: 10.1007/s00262-020-02536-5. doi: 10.1007/s00262-020-02536-5
[11]	Sun X, Roudi R, Dai T, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis[J]. BMC Cancer, 2019,19(1):558. DOI: 10.1186/s12885-019-5701-6. doi: 10.1186/s12885-019-5701-6
[12]	Li M, Spakowicz D, Zhao S, et al. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer[J]. Cancer Immunol Immunother, 2020,69(11):2403-2408. DOI: 10.1007/s00262-020-02674-w. doi: 10.1007/s00262-020-02674-w
[13]	Inoue H, Okamoto I. Immune checkpoint inhibitors for the treatment of unresectable stage Ⅲ non-small cell lung cancer: emerging me-chanisms and perspectives[J]. Lung Cancer (Auckl), 2019,10:161-170. DOI: 10.2147/lctt.S184380.
[14]	Kato T, Masuda N, Nakanishi Y, et al. Nivolumab-induced interstitial lung disease analysis of two phase Ⅱ studies patients with recurrent or advanced non-small-cell lung cancer[J]. Lung Cancer, 2017,104:111-118. DOI: 10.1016/j.lungcan.2016.12.016. doi: 10.1016/j.lungcan.2016.12.016
[15]	Sun Z, Wang S, Du H, et al. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors[J]. Invest New Drugs, 2021, In press. DOI: 10.1007/s10637-020-01051-9.
[16]	Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1[J]. Oncologist, 2016,21(5):643-650. DOI: 10.1634/theoncologist.2015-0498. doi: 10.1634/theoncologist.2015-0498
[17]	Isono T, Kagiyama N, Takano K, et al. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors[J]. Thorac Cancer, 2020,12(2):153-164. DOI: 10.1111/1759-7714.13736. doi: 10.1111/tca.v12.2
[18]	Kanai O, Kim YH, Demura Y, et al. Efficacy and safety of ni-volumab in non-small cell lung cancer with preexisting interstitial lung disease[J]. Thorac Cancer, 2018,9(7):847-855. DOI: 10.1111/1759-7714.12759. doi: 10.1111/tca.2018.9.issue-7
[19]	Tone M, Izumo T, Awano N, et al. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer[J]. Thorac Cancer, 2019,10(10):2006-2012. DOI: 10.1111/1759-7714.13187. doi: 10.1111/tca.v10.10
[20]	Moda M, Saito H, Kato T, et al. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer[J]. Thorac Cancer, 2020,11(12):3576-3584. DOI: 10.1111/1759-7714.13703. doi: 10.1111/tca.v11.12
[21]	Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials[J]. Chest, 2017,152(2):271-281. DOI: 10.1016/j.chest.2017.04.177. doi: S0012-3692(17)30882-6 pmid: 28499515
[22]	Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017,18(7):895-903. DOI: 10.1016/s1470-2045(17)30380-7. doi: 10.1016/S1470-2045(17)30380-7
[23]	Voong KR, Hazell SZ, Fu W, et al. Relationship between prior radio-therapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2019,20(4):e470-e479. DOI: 10.1016/j.cllc.2019.02.018. doi: 10.1016/j.cllc.2019.02.018
[24]	符伶俐, 李萍, 张芮, 等. 胸部肿瘤患者辐射性肺炎的发生和预测因素[J]. 国际肿瘤学杂志, 2020,47(2):107-111. DOI: 10.3760/cma.j.issn.1673-422X.2020.02.009.
[25]	Song P, Zhang D, Cui X, et al. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients[J]. Thorac Cancer, 2020,11(9):2406-2430. DOI: 10.1111/1759-7714.13541. doi: 10.1111/tca.v11.9
[26]	Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature[J]. Cancer, 2018,124(2):271-277. DOI: 10.1002/cncr.31043. doi: 10.1002/cncr.31043 pmid: 28960263
[27]	Peng TR, Tsai FP, Wu TW. Indirect comparison between pembroli-zumab and nivolumab for the treatment of non-small cell lung cancer: a meta-analysis of randomized clinical trials[J]. Int Immunopharmacol, 2017,49:85-94. DOI: 10.1016/j.intimp.2017.05.019. doi: 10.1016/j.intimp.2017.05.019
[28]	Passiglia F, Galvano A, Rizzo S, et al. Looking for the best im-mune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect com-parison between nivolumab, pembrolizumab and atezolizu-mab[J]. Int J Cancer, 2018,142(6):1277-1284. DOI: 10.1002/ijc.31136. doi: 10.1002/ijc.v142.6
[29]	Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018,19(4):521-536. DOI: 10.1016/s1470-2045(18)30144-x. doi: 10.1016/S1470-2045(18)30144-X
[30]	Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2017,18(5):599-610. DOI: 10.1016/s1470-2045(17)30240-1. doi: 10.1016/S1470-2045(17)30240-1
[31]	Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2018,19(11):1468-1479. DOI: 10.1016/s1470-2045(18)30673-9. doi: 10.1016/S1470-2045(18)30673-9
[32]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018,378(22):2093-2104. DOI: 10.1056/NEJMoa1801946. doi: 10.1056/NEJMoa1801946
[33]	Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol, 2019,10:108. DOI: 10.3389/fimmu.2019.00108. doi: 10.3389/fimmu.2019.00108
[34]	Antonia SJ, Villegas A, Daniel D, et al. Overall survival with dur-valumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018,379(24):2342-2350. DOI: 10.1056/NEJMoa1809697. doi: 10.1056/NEJMoa1809697
[35]	陈康, 孙步彤. PD-1/PD-L1抑制剂在晚期肿瘤患者中的相关肺炎发生率和发生风险:一项荟萃分析[J]. 中国肺癌杂志, 2020,23(11):927-940. DOI: 10.3779/j.issn.1009-3419.2020.103.14.
[36]	Lisberg A, Cummings A, Goldman JW, et al. A phase Ⅱ study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC[J]. J Thorac Oncol, 2018,13(8):1138-1145. DOI: 10.1016/j.jtho.2018.03.035. doi: S1556-0864(18)30602-6 pmid: 29874546
[37]	Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer[J]. JAMA Oncol, 2018,4(8):1112-1115. DOI: 10.1001/jamaoncol.2017.4526. doi: 10.1001/jamaoncol.2017.4526 pmid: 29327061
[38]	Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ⅰb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020,31(4):507-516. DOI: 10.1016/j.annonc.2020.01.013. doi: 10.1016/j.annonc.2020.01.013
[39]	Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with dur-valumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ⅰb trial[J]. J Thorac Oncol, 2016,11(4):s115 DOI: 10.1016/s1556-0864(16)30246-5.
[40]	Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv119-iv142. DOI: 10.1093/annonc/mdx225.
[41]	mBrahmer JR, Lacchetti C, Schneider BJ, et al. Management of im-mune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline[J]. J Oncol Pract, 2018,36(17):1714-1768. DOI: 10.1200/jco.2017.77.6385.
[42]	Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2018,36(28):2872-2878. DOI: 10.1200/jco.2018.79.0006. doi: 10.1200/JCO.2018.79.0006
[43]	Utsumi H, Araya J, Okuda K, et al. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report[J]. Cancer Immunol Immunother, 2020,69(10):2033-2039. DOI: 10.1007/s00262-020-02600-0. doi: 10.1007/s00262-020-02600-0
[44]	Martins F, Sykiotis GP, Maillard M, et al. New therapeutic perspec-tives to manage refractory immune checkpoint-related toxicities[J]. Lancet Oncol, 2019,20(1):e54-e64. DOI: 10.1016/s1470-2045(18)30828-3. doi: 10.1016/S1470-2045(18)30828-3
[45]	Frye BC, Meiss F, Von Bubnoff D, et al. Vasoactive intestinal peptide in checkpoint inhibitor-induced pneumonitis[J]. N Engl J Med, 2020,382(26):2573-2574. DOI: 10.1056/NEJMc2000343. doi: 10.1056/NEJMc2000343
[46]	Sehgal S, Velcheti V, Mukhopadhyay S, et al. Focal lung infiltrate complicating PD-1 inhibitor use: a new pattern of drug-associated lung toxicity?[J]. Respir Med Case Rep, 2016,19:118-120. DOI: 10.1016/j.rmcr.2016.09.001.
[47]	Suresh K, Naidoo J, Zhong Q, et al. The alveolar immune cell land-scape is dysregulated in checkpoint inhibitor pneumonitis[J]. J Clin Invest, 2019,129(10):4305-4315. DOI: 10.1172/jci128654. doi: 10.1172/JCI128654
[48]	Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer[J]. Lung Cancer, 2017,106:1-7. DOI: 10.1016/j.lungcan.2017.01.013. doi: 10.1016/j.lungcan.2017.01.013
[49]	Owen DH, Wei L, Bertino EM, et al. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer[J]. Clin Lung Cancer, 2018,19(6):e893-e900. DOI: 10.1016/j.cllc.2018.08.008. doi: 10.1016/j.cllc.2018.08.008
[50]	Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J]. Lung Can-cer, 2020,150:76-82. DOI: 10.1016/j.lungcan.2020.08.015.
[51]	Carretero R, Sektioglu IM, Garbi N, et al. Corrigendum: eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells[J]. Nat Immunol, 2016,17(2):214. DOI: 10.1038/ni0216-214b.
[52]	Fukihara J, Sakamoto K, Koyama J, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors[J]. Clin Lung Cancer, 2019, 20(6): 442-450.e4. DOI: 10.1016/j.cllc.2019.07.006. doi: S1525-7304(19)30210-4 pmid: 31446020
[53]	Zeng J, Rengan R, Santana-Davila R, et al. Early assessment of liquid biomarkers to predict pneumonitis after chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC)[G]. AACR, Philadelphia, USA, 2020.
[54]	Yoshida K, Morishima Y, Shiozawa T, et al. Serum soluble inter-leukin-2 receptor as a possible biomarker for the early detection and follow-up of nivolumab-induced pneumonitis[J]. J Thorac Oncol, 2019,14(5):e90-e91. DOI: 10.1016/j.jtho.2018.12.028. doi: 10.1016/j.jtho.2018.12.028
[55]	Wang YN, Lou DF, Li DY, et al. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer[J]. Oncol Lett, 2020,20(1):611-622. DOI: 10.3892/ol.2020.11618. doi: 10.3892/ol.2020.11618 pmid: 32565986